The Journal of infection · 2026
Population pharmacokinetics of amikacin in patients with a haematological disorder: A prospective, observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dräger Sarah, Müller Sereina Livia, Bausch Severin, Weisser Maja, Halter Jörg, Rentsch Katharina, Sassen Sebastiaan D T, Koch Birgit C P, Bassetti Stefano, Gotta Verena, Osthoff Michael
Аннотация
OBJECTIVES: To assess amikacin target attainment in patients with a haematological disorder treated for febrile neutropenia or severe infection and to develop a population pharmacokinetic (PK) model.
METHODS: This prospective observational single-centre study was conducted at the University Hospital Basel, Switzerland between December 2022 and February 2024. Adult patients with a haematological disorder treated with amikacin for 1-3 days were included. Total amikacin concentrations in blood were measured 1 h and 8 h after each administration. The primary objective was target attainment (Cmax ≥60 mg/L) at all time points evaluated (in the context of the amikacin ECOFF of 8 mg/L for Enterobacterales). A population PK model was developed to derive individual exposure estimates.
RESULTS: Overall, 57 patients with 119 amikacin applications and 174 concentration measurements were included. The median age was 61 years [interquartile range (IQR) 53-68] and 33% were female. Targets of Cmax ≥60 mg/L were attained in 11/57 patients (19.3%) and Cmax/MIC≥8 in 10/10 patients (100%), in whom a pathogen was identified. In the population PK model, weight and GFR were correlated with PK parameters in the multivariable analysis.
CONCLUSIONS: Amikacin target attainment was low in patients with a haematological malignancy treated empirically for FN, when pathogens with higher MICs are considered. Dosing optimisation may be needed to improve target attainment.
METHODS: This prospective observational single-centre study was conducted at the University Hospital Basel, Switzerland between December 2022 and February 2024. Adult patients with a haematological disorder treated with amikacin for 1-3 days were included. Total amikacin concentrations in blood were measured 1 h and 8 h after each administration. The primary objective was target attainment (Cmax ≥60 mg/L) at all time points evaluated (in the context of the amikacin ECOFF of 8 mg/L for Enterobacterales). A population PK model was developed to derive individual exposure estimates.
RESULTS: Overall, 57 patients with 119 amikacin applications and 174 concentration measurements were included. The median age was 61 years [interquartile range (IQR) 53-68] and 33% were female. Targets of Cmax ≥60 mg/L were attained in 11/57 patients (19.3%) and Cmax/MIC≥8 in 10/10 patients (100%), in whom a pathogen was identified. In the population PK model, weight and GFR were correlated with PK parameters in the multivariable analysis.
CONCLUSIONS: Amikacin target attainment was low in patients with a haematological malignancy treated empirically for FN, when pathogens with higher MICs are considered. Dosing optimisation may be needed to improve target attainment.